Ceramide remodeling in MASLD: linking lipid-fate reprogramming to organelle stress, inflammation, and fibrosis

Metabolic dysfunction-associated steatotic liver disease (MASLD) is closely linked to obesity, insulin resistance, and metabolic overload, but hepatic fat accumulation alone does not explain its heterogeneous progression to steatohepatitis, fibrosis, and cirrhosis. Ceramide denotes a bioactive sphingolipid class whose members are generated through de novo synthesis, sphingomyelin hydrolysis, and salvage/recycling pathways. Its biological effects depend on molecular species, metabolic flux, cellular source, and subcellular localization as well as abundance. Human evidence, however, remains heterogeneous and predominantly cross-sectional: no reproducible ceramide-specific signature has been established across the reviewed cohorts and clinical endpoints, and circulating concentrations cannot be assumed to represent hepatocyte or organelle-specific pools. Associations therefore do not establish whether altered ceramide profiles reflect drivers, consequences, or biomarkers of metabolic dysfunction. We use ceramide remodeling as a conceptual umbrella whose individual dimensions require distinct experimental measurements, rather than as a single standardized biological state. Integrating species-resolved lipidomics with source-specific perturbation studies, we propose a context-dependent framework linking lipid-fate reprogramming to organelle stress and inflammatory–fibrotic amplification. Direct mechanistic and therapeutic evidence remains largely preclinical, whereas human findings are interpreted separately by sample compartment, study design, endpoint, and validation status. Limited longitudinal observations support further prognostic investigation but require independent replication. This framework organizes testable hypotheses for spatially resolved causal studies and interventions with empirically defined therapeutic windows; neither clinical utility nor the superiority of selective over broadly distributed treatment has been established.

Authors

Institutions

Publication Details

Journal
Frontiers in Medicine
Published
2026-11-13
DOI
https://doi.org/10.3389/fmed.2026.1972800
Primary Topic
Sphingolipid Metabolism and Signaling
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Ceramide remodeling in MASLD: linking lipid-fate reprogramming to organelle stress, inflammation, and fibrosis

Lin Qi, Yang Du, Xiaoyang Hu, Bojia Li et al.
5 links
Frontiers in Medicine
Sphingolipid Metabolism and Signaling
article

Ceramide remodeling in MASLD: linking lipid-fate reprogramming to organelle stress, inflammation, and fibrosis

Lin Qi, Yang Du, Xiaoyang Hu, Bojia Li, Yunze Shi, Mingfeng Liu, Xingyuan Huang, Boqi Ren
article en

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) is closely linked to obesity, insulin resistance, and metabolic overload, but hepatic fat accumulation alone does not explain its heterogeneous progression to steatohepatitis, fibrosis, and cirrhosis. Ceramide denotes a bioactive sphingolipid class whose members are generated through de novo synthesis, sphingomyelin hydrolysis, and salvage/recycling pathways. Its biological effects depend on molecular species, metabolic flux, cellular source, and subcellular localization as well as abundance. Human evidence, however, remains heterogeneous and predominantly cross-sectional: no reproducible ceramide-specific signature has been established across the reviewed cohorts and clinical endpoints, and circulating concentrations cannot be assumed to represent hepatocyte or organelle-specific pools. Associations therefore do not establish whether altered ceramide profiles reflect drivers, consequences, or biomarkers of metabolic dysfunction. We use ceramide remodeling as a conceptual umbrella whose individual dimensions require distinct experimental measurements, rather than as a single standardized biological state. Integrating species-resolved lipidomics with source-specific perturbation studies, we propose a context-dependent framework linking lipid-fate reprogramming to organelle stress and inflammatory–fibrotic amplification. Direct mechanistic and therapeutic evidence remains largely preclinical, whereas human findings are interpreted separately by sample compartment, study design, endpoint, and validation status. Limited longitudinal observations support further prognostic investigation but require independent replication. This framework organizes testable hypotheses for spatially resolved causal studies and interventions with empirically defined therapeutic windows; neither clinical utility nor the superiority of selective over broadly distributed treatment has been established.

Frontiers in MedicineVol. 13
Heilongjiang University of Chinese Medicine (CN)
National Natural Science Foundation of China, Natural Science Foundation of Heilongjiang Province
Good health and well-being
Sphingolipid Metabolism and Signaling
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon